Part 8
The first push of bodies knocked Mara’s chair sideways. Daniel caught her arm, but the aisle filled before they could reach it. Someone shouted that the elevators were locked. Another person climbed over a row of seats. The orderly hearing became a current pouring toward one stairwell.
Ranger rose against his handler’s cue. He did not know the words bomb threat; he knew pressure, Mara’s imbalance, and the route Daniel indicated. He placed his body across the opening beside a support column, creating a pocket long enough for Daniel to pull Mara out of the crush. His wounded shoulder dipped. Mara gripped the harness and kept him upright while a security officer opened a second exit.
They reached the street with Tessa and Leah. Fire engines blocked the avenue, and bomb technicians entered while hundreds of people waited behind barricades in the December wind. No one knew whether the threat was connected to the hearing, a general hoax, or something else. Leah turned an accusatory message face down and asked an officer for an evidence receipt. “My editor gets what I can source,” she said. “This isn’t sourced.”
After seventy minutes, the sweep found no device. The building reopened under controlled entry, though half the observers chose not to return. Denise held out the hotel key card and said she could request an adjournment.
Mara looked at Ranger leaning against Daniel, favoring his mended shoulder but breathing evenly. “He goes to the car with the veterinary tech,” she said. “And I go back upstairs.” Daniel called the tech without arguing. That was the agreement they had made in Ben’s room, put into practice when it cost them something.
Security rearranged the chamber. The chair stated for the record that the source of the threat was unknown and the proceeding would continue. Mara resumed her seat without Ranger at her feet. His absence made the space feel enormous.
The laboratory director testified remotely about the vial’s chemical profile and chain of custody. She could say it contained the active study compound. She could not say why Ben took it, whether he ever used it, or whether receiving it would have altered his disease. A trial auditor confirmed that the consent versions provided by four families did not authorize concealed reassignment. Tessa’s source files matched backups obtained that morning from the study monitor under subpoena.
Vale’s attorney argued that a coordinator might revise administrative pages after signature without changing substance. The auditor enlarged the missing paragraph: it described the possibility of receiving an inactive carrier. In the family copies, that paragraph did not exist. In the archived versions, it appeared beneath earlier signatures.
“That is not formatting,” the auditor said.
Vale insisted another team handled consent storage. The chair asked why his account approved the revisions. He said shared credentials were common. Tessa quietly supplied the policy he had signed prohibiting them.
Then Mara asked to place Ben’s original note into the administrative record.
Denise had warned her that she might not get it back for months. It was the last thing Ben had written directly to her, the page his hands had folded and hidden. Mara carried it to the clerk anyway. Keeping it close had begun to feel like another form of burial.
She read from the authenticated copy. Her voice broke only on I’m sorry I got scared. When she finished, she did not call Ben’s fear a sacrifice.
“My son did not volunteer for what happened to him,” she told the panel. “He was ten. He could not consent to a secret allocation, and he could not know whether this compound would save him. He gathered what he could because the adults around him made honest answers impossible. Please do not praise him in a way that excuses us for leaving that burden with a child.”
Dr. Vale lowered his head.
The board chair turned to Shaw. She displayed a scanned consent form beside its revision history and an executive email thread. “Your office received notice at nine-fourteen that the disclosure page had been replaced after signature. Is that your address in the header?”
Shaw conferred with counsel. “Yes.”
“At nine-twenty-two, that address replied, ‘Do what is necessary before the investor call.’ Did you send that instruction?”
His lawyer objected that the phrase referred to participant safety. The chair overruled the objection and asked again. Shaw looked at the timestamp, then at the allocation chart projected beside it.
“I sent the email,” he said.
The chair entered the answer without interpreting it. The record now placed Shaw’s instruction after notice of the altered disclosure and before the investor call he had said clinical staff handled without him. It was not a conviction or a full confession. It was a documented contradiction the panel could evaluate without guessing at his motive.
The panel recessed for two hours. When it returned, the chair issued an interim order. N-17 was suspended. Every participant would be notified of the allocation discrepancies, offered independent clinical review, and given an accurate copy of the consent and treatment record. Lakeshore had to preserve all data. Vale’s research privileges were temporarily restricted pending a licensing inquiry. The complete record would be referred to federal trial regulators and investigators for any civil or criminal action within their authority.
“This panel makes no finding of criminal guilt today,” the chair said. “Our immediate duty is participant safety.”
Outside, two federal investigators asked Mara, Daniel, and Tessa to schedule separate interviews. Denise reminded them that referrals could take months or years and might not end as they hoped. Mara believed her. The grand finish promised by anger had become paperwork, sworn statements, and children sent to doctors unconnected to Solace.
On Daniel’s phone, the public trial listing refreshed. Beside N-17, one word appeared in red: SUSPENDED.
To read the rest of the story – CLICK the NEXT button 👇👇👇